Claims
- 1. A compound of the formula: ##STR24## wherein Ra is nitro or cyano, Rb is hydrogen or halogen and Rc' is COR.sup.11 wherein R.sup.11 is an aromatic or partially unsaturated heterocyclic group attached via a ring carbon atom and having 1-3 nitrogen atoms as hetero ring members,
- or an ester or ether derivative thereof which is hydrolyzable under physiological conditions or a pharmaceutically acceptable salt thereof.
- 2. A compound, according to claim 1, wherein Rb is situated in the p-position to Ra.
- 3. A compound, according to claim 2, wherein Ra is nitro.
- 4. A compound, according to claim 3, wherein Rb is hydrogen, chlorine or fluorine.
- 5. A compound, according to claim 4, wherein Rb is hydrogen.
- 6. A compound, according to claim 5, wherein Rc' is the group -CO-R.sup.11 and R.sup.11 is an aromatic, mononuclear heterocyclic group with 1-3 nitrogen atoms as the hetero ring member(s) which is attached via a carbon atom.
- 7. A compound, according to Claim 6, wherein R.sup.11 is a pyridyl group.
- 8. A compound, according to claim 1, 3,4-Dihydroxy-5-nitrophenyl 4-pyridyl ketone.
- 9. A compound according to claim 1, 3,4-dihydroxy-5-nitrophenyl 3-pyridyl ketone.
- 10. A pharmaceutical composition comprising a compound of the formula: ##STR25## wherein Ra is nitro or cyano, Rb is hydrogen or halogen and Rc' is COR.sup.1 wherein R.sup.1 is an aromatic or partially unsaturated heterocyclic group attached via a ring carbon atom and having 1-3 nitrogen atoms as hetero ring members,
- or an ester or ether derivative thereof which is hydrolyzable under physiological conditions or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier material.
- 11. A pharmaceutical composition, according to claim 10, wherein the compound of formula Ia is 3,4-dihydroxy-5-nitrophenyl 4-pyridyl ketone.
- 12. A pharmaceutical composition according to claim 10, wherein the compound of formula Ia is 3,4-dihydroxy-5-nitrophenyl 3-pyridyl ketone.
- 13. A pharmaceutical composition comprising L-dopa, peripheral decarboxylase inhibitor, a compound of the formula: ##STR26## wherein Ra is nitro or cyano, Rb is hydrogen or halogen and Rc' is COR.sup.1 wherein R.sup.1 is an aromatic or partially unsaturated heterocyclic group attached via a ring carbon atom and having 1-3 nitrogen atoms as hereto ring members,
- or an ester or ether derivative thereof which is hydrolyzable under physiological conditions or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier material.
- 14. A pharmaceutical composition according to claim 10, wherein R.sup.1 is pyridyl.
- 15. A pharmaceutical composition according to claim 14, wherein the compound of formula Ia is 3,4-dihydroxy-5-nitrophenyl 3-pyridyl ketone.
- 16. A pharmaceutical composition for treating depression comprising an effective amount of a compound of the formula: ##STR27## wherein Ra is nitro or cyano, Rb is hydrogen or halogen and Rc' is COR.sup.1 wherein R.sup.l is an aromatic or partially unsaturated heterocyclic group attached via a ring carbon atom and having 1-3 nitrogen atoms as hereto ring members,
- or an ester or ether derivative thereof which is hydrolyzable under physiological conditions or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier material.
- 17. A pharmaceutical composition according to claim 16, wherein R.sup.1 is pyridyl.
- 18. A pharmaceutical composition according to claim 17, wherein the compound of formula Ia is 3,4-dihydroxy-5-nitrophenyl 3-pyridyl ketone.
- 19. A pharmaceutical composition for treating Parkinson's disease comprising L-dopa, a peripheral decarboxylase inhibitor, a compound of the formula: ##STR28## wherein Ra is nitro or cyano, Rb is hydrogen or halogen and Rc' is COR.sup.1 wherein R.sup.1 is an aromatic or partially unsaturated heterocyclic group attached via a ring carbon atom and having 1-3 nitrogen atoms as hereto ring members,
- or an ester or ether derivative thereof which is hydrolyzable under physiological conditions or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier material.
- 20. A pharmaceutical composition according to claim 19, wherein R.sup.1 is pyridyl.
- 21. A pharmaceutical composition according to claim 20, wherein the compound of formula Ia is 3,4-dihydroxy-5-nitrophenyl 3-pyridyl ketone.
- 22. A pharmaceutical composition for inhibiting catechol-O-methyl-transferase, said composition comprising a catechol-O-methyl transferase inhibiting amount of a compound of the formula: ##STR29## wherein Ra is nitro or cyano, Rb is hydrogen or halogen and Rc' is COR.sup.1 wherein R.sup.1 is an aromatic or partially unsaturated heterocyclic group attached via a ring carbon atom and having 1-3 nitrogen atoms as hereto ring members,
- or an ester or ether derivative thereof which is hydrolyzable under physiological conditions or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier material.
- 23. A pharmaceutical composition according to claim 22, wherein R.sup.1 is pyridyl.
- 24. A pharmaceutical composition according to claim 23, wherein the compound of formula Ia is 3,4-dihydroxy-5-nitrophenyl 3-pyridyl ketone.
Priority Claims (2)
Number |
Date |
Country |
Kind |
980/86 |
Mar 1986 |
CHX |
|
62/87 |
Jan 1987 |
CHX |
|
Parent Case Info
This is a continuation of application Ser. No. 07/686,210, filed Apr. 16, 1991, now U.S. Pat. No. 5,236,952, which is a Rule 60 Continuation of Ser. No. 07/395,110, filed Aug. 16, 1989, now Abandoned, which is a Rule 60 Continuation of Ser. No. 022,891, filed Mar. 6, 1987, now Abandoned.
Non-Patent Literature Citations (2)
Entry |
Chemical Abstracts, vol. 115, No. 5, Abstract 49134d, p. 790 Aug. 5, 1991, Bernauer et al. |
Borgulya et al., Helv. Chim. Acta, vol. 72(5), pp. 952-968, 1989. |
Continuations (3)
|
Number |
Date |
Country |
Parent |
686210 |
Apr 1991 |
|
Parent |
395110 |
Aug 1989 |
|
Parent |
22891 |
Mar 1987 |
|